SI2668184T1 - PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT - Google Patents
PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT Download PDFInfo
- Publication number
- SI2668184T1 SI2668184T1 SI201231273T SI201231273T SI2668184T1 SI 2668184 T1 SI2668184 T1 SI 2668184T1 SI 201231273 T SI201231273 T SI 201231273T SI 201231273 T SI201231273 T SI 201231273T SI 2668184 T1 SI2668184 T1 SI 2668184T1
- Authority
- SI
- Slovenia
- Prior art keywords
- group
- compound
- compound according
- atom
- optionally substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 5
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 title claims 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical class C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 24
- 239000000203 mixture Substances 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- 108060006706 SRC Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- -1 (C 1 -C 6 alkyl Chemical group 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1150651A FR2970967B1 (fr) | 2011-01-27 | 2011-01-27 | Derives de type azaindazole ou diazaindazole comme medicament |
| EP12701884.4A EP2668184B1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
| PCT/EP2012/051283 WO2012101239A1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2668184T1 true SI2668184T1 (en) | 2018-06-29 |
Family
ID=44318089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231273T SI2668184T1 (en) | 2011-01-27 | 2012-01-27 | PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20130172360A1 (enExample) |
| EP (1) | EP2668184B1 (enExample) |
| JP (1) | JP5931926B2 (enExample) |
| KR (2) | KR101923751B1 (enExample) |
| CN (1) | CN103339129B (enExample) |
| AR (1) | AR084935A1 (enExample) |
| AU (1) | AU2012210467B2 (enExample) |
| BR (1) | BR112013018852B1 (enExample) |
| CA (1) | CA2823824C (enExample) |
| CY (1) | CY1120088T1 (enExample) |
| DK (1) | DK2668184T3 (enExample) |
| ES (1) | ES2661695T3 (enExample) |
| FR (1) | FR2970967B1 (enExample) |
| HR (1) | HRP20180524T1 (enExample) |
| HU (1) | HUE037153T2 (enExample) |
| IL (2) | IL227496B (enExample) |
| LT (1) | LT2668184T (enExample) |
| MA (1) | MA34903B1 (enExample) |
| MX (1) | MX356411B (enExample) |
| MY (1) | MY180666A (enExample) |
| PL (1) | PL2668184T3 (enExample) |
| PT (1) | PT2668184T (enExample) |
| RS (1) | RS57101B1 (enExample) |
| RU (1) | RU2600976C2 (enExample) |
| SI (1) | SI2668184T1 (enExample) |
| TN (1) | TN2013000293A1 (enExample) |
| TR (1) | TR201802944T4 (enExample) |
| TW (1) | TWI546303B (enExample) |
| UA (1) | UA109698C2 (enExample) |
| WO (1) | WO2012101239A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| BR112014020773A2 (pt) | 2012-02-22 | 2020-10-27 | Sanford-Burnham Medical Research Institute | compostos de sulfonamida e seus usos como inibidores tnap |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| HUE036571T2 (hu) | 2013-04-19 | 2018-07-30 | Incyte Holdings Corp | Biciklusos heterociklusok mint FGFR inhibitorok |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10336707B2 (en) | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| MX388991B (es) | 2015-02-20 | 2025-03-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr) |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10211205B2 (en) * | 2016-04-27 | 2019-02-19 | International Business Machines Corporation | Field effect transistor structure for reducing contact resistance |
| CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102653799B1 (ko) * | 2018-05-02 | 2024-04-03 | 제이더블유중외제약 주식회사 | 신규한 헤테로 사이클 유도체 |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| EP3788047B1 (en) | 2018-05-04 | 2024-09-04 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220100879A (ko) | 2019-10-14 | 2022-07-18 | 인사이트 코포레이션 | Fgfr 저해제로서의 이환식 헤테로사이클 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202136255A (zh) * | 2019-12-31 | 2021-10-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與ｓｔｉｎｇ活性相關之病狀的化合物及組合物 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115916771B (zh) * | 2020-04-02 | 2025-04-01 | 浙江华海药业股份有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| GB2617477A (en) * | 2020-11-20 | 2023-10-11 | 2692372 Ontario Inc | Benzenesulfonamide derivatives and uses thereof |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000076426A (ko) * | 1997-03-19 | 2000-12-26 | 스타르크, 카르크 | 피롤로[2,3-ｄ]피리미딘 및 티로신 키나제 저해제로서의 그의 용도 |
| EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
| AU6259701A (en) | 2000-06-22 | 2002-01-02 | Dunn Peter James | Process for the preparation of pyrazolopyrimidinones |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| CA2620254A1 (en) * | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
| JP2009543867A (ja) | 2006-07-17 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物 |
| DK2120932T3 (da) | 2006-12-20 | 2014-10-13 | Nerviano Medical Sciences Srl | Indazolderivater som kinasehæmmere til behandling af kræft |
| JP5506674B2 (ja) | 2007-07-20 | 2014-05-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換インダゾール誘導体 |
| US8354399B2 (en) | 2008-12-18 | 2013-01-15 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
-
2011
- 2011-01-27 FR FR1150651A patent/FR2970967B1/fr active Active
-
2012
- 2012-01-20 TW TW101102531A patent/TWI546303B/zh active
- 2012-01-27 PL PL12701884T patent/PL2668184T3/pl unknown
- 2012-01-27 MX MX2013008673A patent/MX356411B/es active IP Right Grant
- 2012-01-27 RU RU2013138624/04A patent/RU2600976C2/ru active
- 2012-01-27 CN CN201280006671.8A patent/CN103339129B/zh not_active Expired - Fee Related
- 2012-01-27 RS RS20180418A patent/RS57101B1/sr unknown
- 2012-01-27 KR KR1020137022330A patent/KR101923751B1/ko not_active Expired - Fee Related
- 2012-01-27 DK DK12701884.4T patent/DK2668184T3/en active
- 2012-01-27 LT LTEP12701884.4T patent/LT2668184T/lt unknown
- 2012-01-27 HR HRP20180524TT patent/HRP20180524T1/hr unknown
- 2012-01-27 BR BR112013018852-9A patent/BR112013018852B1/pt not_active IP Right Cessation
- 2012-01-27 MY MYPI2013002799A patent/MY180666A/en unknown
- 2012-01-27 PT PT127018844T patent/PT2668184T/pt unknown
- 2012-01-27 EP EP12701884.4A patent/EP2668184B1/en active Active
- 2012-01-27 JP JP2013550886A patent/JP5931926B2/ja active Active
- 2012-01-27 UA UAA201310425A patent/UA109698C2/ru unknown
- 2012-01-27 US US13/823,658 patent/US20130172360A1/en not_active Abandoned
- 2012-01-27 TR TR2018/02944T patent/TR201802944T4/tr unknown
- 2012-01-27 SI SI201231273T patent/SI2668184T1/en unknown
- 2012-01-27 HU HUE12701884A patent/HUE037153T2/hu unknown
- 2012-01-27 KR KR1020187031264A patent/KR20180122028A/ko not_active Ceased
- 2012-01-27 ES ES12701884.4T patent/ES2661695T3/es active Active
- 2012-01-27 MA MA36177A patent/MA34903B1/fr unknown
- 2012-01-27 WO PCT/EP2012/051283 patent/WO2012101239A1/en not_active Ceased
- 2012-01-27 AU AU2012210467A patent/AU2012210467B2/en not_active Ceased
- 2012-01-27 CA CA2823824A patent/CA2823824C/en active Active
- 2012-01-27 AR ARP120100272A patent/AR084935A1/es active IP Right Grant
- 2012-11-27 US US13/686,334 patent/US8883821B2/en active Active
-
2013
- 2013-07-11 TN TNP2013000293A patent/TN2013000293A1/fr unknown
- 2013-07-16 IL IL227496A patent/IL227496B/en active IP Right Grant
-
2018
- 2018-02-26 IL IL257748A patent/IL257748B/en active IP Right Grant
- 2018-03-26 CY CY20181100338T patent/CY1120088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2668184T1 (en) | PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT | |
| HRP20170104T1 (hr) | Derivati tipa azaindazola ili diazaindazola za liječenje boli | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2014503574A5 (enExample) | ||
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20180212T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| JP2017511360A5 (enExample) | ||
| JP2013523614A5 (enExample) | ||
| RU2010121763A (ru) | Производные пиридазинона и ингибиторы р2х7 рецептора | |
| DE69925141D1 (de) | Chinazolin derivate | |
| IL302896A (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| RS51861B2 (sr) | Heterociklični inhibitori mek-a | |
| CA2572208A1 (en) | 3-carbamoyl-2-pyridone derivative | |
| JP2014510774A5 (enExample) | ||
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| HRP20161786T1 (hr) | Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze | |
| RU2012142730A (ru) | Соединения, композиции и способы для снижения или устранения горького вкуса | |
| HRP20110156T1 (hr) | Monociklički heterocikli kao inhibitori kinaze | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| HRP20171638T1 (hr) | Derivati pirazolin diona kao inhibitori nadph oksidaze | |
| PH12021552201A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| HRP20150954T1 (hr) | Derivati dialkoksikinazolina kao inhibitori kdr |